March 25th 2024
A phase 2 trial plans to evaluate BAT8006 for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Part 1: PARP Inhibition Recommendations in Advanced Ovarian Cancer
January 12th 2022During a live virtual event, Matthew L. Anderson, MD, PhD, discusses the National Comprehensive Cancer Network guidelines for treating patients with advanced ovarian cancer using PARP inhibitors based on BRCA mutation status and other factors.
Read More
The Potential of Rebastinib in Platinum-Resistant Ovarian Cancer Treatment
November 29th 2021Erika Hamilton, MD, discusses the mechanism of action of rebastinib, which is currently being explored in combination with weekly paclitaxel 1b/2 study of patients with platinum-resistant ovarian cancer.
Watch
Updated SOLO1 Safety Data Show Olaparib Maintenance is Safe in BRCA-Positive Ovarian Cancer
October 27th 2021Patients with advanced ovarian cancer who respond to platinum-based chemotherapy are eligible for olaparib monotherapy. Data from the SOLO1 trial found that the safety profile of the agent is manageable.
Read More